Collectively, in vitro experimental data suggests that inhibition of PP2A by LB-100 enhances the cytotoxicity of CAR-T cells and augments adaptive immune resistance in CAR-T treated tumor cells via increased expression of PD-L1. The gene discussed is CD274; the disease is neoplasm.